Treatment Patterns and Clinical Outcomes for Multiple Myeloma in Korean Patients: a Database Study

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2025 Feb 28

PMID 40022009

Authors

Junghyun Yoon

Jongheon Jung

Boyoung Park

Eunyoung Lee

YoungJu Park

Soomin Yoon

Hyeon-Seok Eom

Affiliations

Soon will be listed here.

Abstract

Background: The treatment landscape for multiple myeloma (MM) has significantly progressed in recent decades.

Methods: We analyzed the treatment patterns and clinical outcomes in Korean patients using data from the National Health Insurance Service database. Patients diagnosed with MM between 2010 and 2018 were included. Survival analysis with a Cox regression model was performed.

Results: A total of 8,367 patients with MM were identified, from which 2,442 patients underwent stem cell transplantation (SCT). The mean patients' age at diagnosis was 67.1 years. Since 2011, the combination of a proteasome inhibitor (PI) and an alkylating agent has been most common, with a significant increase in the PI and immunomodulatory drug (IMiD) combination after 2015. The attrition rates after first-line therapy were 45% and 56% for the SCT and non-SCT groups, respectively. Patients on bortezomib, melphalan, and prednisolone were younger with less renal insufficiency compared to those on lenalidomide and dexamethasone. The SCT group had a median overall survival (OS) of 7.04 years, significantly higher than the non-SCT group's 2.52 years.

Conclusions: SCT eligibility and the reimbursement status of new drugs impact the treatment pattern of MM. Expanding access to new agents and identifying patients who can benefit from SCT are essential.

References

Kang M, Won Y, Lee J, Jung K, Kim H, Kong H . Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019. Cancer Res Treat. 2022; 54(2):330-344. PMC: 9016309. DOI: 10.4143/crt.2022.128. View

Facon T, San-Miguel J, Dimopoulos M, Mateos M, Cavo M, van Beekhuizen S . Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. Adv Ther. 2022; 39(5):1976-1992. PMC: 9056460. DOI: 10.1007/s12325-022-02083-8. View

Fu W, Bang S, Huang H, Kim K, Li W, An G . Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study. Clin Lymphoma Myeloma Leuk. 2023; 23(6):446-455.e4. DOI: 10.1016/j.clml.2023.02.009. View

San Miguel J, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M . Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359(9):906-17. DOI: 10.1056/NEJMoa0801479. View

Swan D, Murphy P, Glavey S, Quinn J . Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety. Cancers (Basel). 2023; 15(6). PMC: 10046900. DOI: 10.3390/cancers15061819. View

Lu J, Lee J, Huang S, Qiu L, Lee J, Liu T . Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. Br J Haematol. 2017; 176(5):743-749. PMC: 5324608. DOI: 10.1111/bjh.14465. View

Park B, Lee E, Yoon J, Park Y, Eom H . Secondary Malignancies in Multiple Myeloma in Korean Patients: A Nationwide Population-Based Study. Cancer Res Treat. 2023; 56(3):936-944. PMC: 11261182. DOI: 10.4143/crt.2023.843. View

Siegel R, Giaquinto A, Jemal A . Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1):12-49. DOI: 10.3322/caac.21820. View

Ailawadhi S, Jagannath S, Narang M, Rifkin R, Terebelo H, Toomey K . Connect MM Registry as a national reference for United States multiple myeloma patients. Cancer Med. 2019; 9(1):35-42. PMC: 6943143. DOI: 10.1002/cam4.2656. View

10.

Chari A, Minnema M, Berdeja J, Oriol A, van de Donk N, Rodriguez-Otero P . Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022; 387(24):2232-2244. DOI: 10.1056/NEJMoa2204591. View

11.

Richardson P, Jacobus S, Weller E, Hassoun H, Lonial S, Raje N . Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022; 387(2):132-147. PMC: 10040899. DOI: 10.1056/NEJMoa2204925. View

12.

Sonneveld P, Dimopoulos M, Boccadoro M, Quach H, Ho P, Beksac M . Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2023; 390(4):301-313. DOI: 10.1056/NEJMoa2312054. View

13.

Rajkumar S . Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020; 95(5):548-567. DOI: 10.1002/ajh.25791. View

14.

Kouroukis T, Baldassarre F, Haynes A, Imrie K, Reece D, Cheung M . Bortezomib in multiple myeloma: systematic review and clinical considerations. Curr Oncol. 2014; 21(4):e573-603. PMC: 4117625. DOI: 10.3747/co.21.1798. View

15.

Puertas B, Gonzalez-Calle V, Sobejano-Fuertes E, Escalante F, Queizan J, Barez A . Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. Cancers (Basel). 2023; 15(5). PMC: 10000382. DOI: 10.3390/cancers15051558. View

16.

Jung J, Choi Y, Lee J, Lee W, Kim S, Park Y . Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. Int J Hematol. 2020; 112(1):84-95. DOI: 10.1007/s12185-020-02869-y. View

17.

Mateos M, Dimopoulos M, Cavo M, Suzuki K, Jakubowiak A, Knop S . Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2017; 378(6):518-528. DOI: 10.1056/NEJMoa1714678. View

18.

Kumar S, Rajkumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F . Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2007; 111(5):2516-20. PMC: 2254544. DOI: 10.1182/blood-2007-10-116129. View

19.

Moreau P, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A . Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022; 387(6):495-505. PMC: 10587778. DOI: 10.1056/NEJMoa2203478. View

20.

Benboubker L, Dimopoulos M, Dispenzieri A, Catalano J, Belch A, Cavo M . Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014; 371(10):906-17. DOI: 10.1056/NEJMoa1402551. View